Background/Aim: Perioperative nutrition and inflammation affect the oncological outcomes of various malignancies. We evaluated the clinical impact of the preoperative platelet-to-albumin ratio (PAR) in resectable esophageal cancer patients who received curative treatment. Patients and Methods: This study included 168 patients who underwent curative surgery followed by perioperative adjuvant chemotherapy for esophageal cancer between 2005 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified. Results: Based on the 3-and 5-year OS rates, we set the cut-off value for the PAR at 80×10 3 in the present study. Among 168 patients, 134 (79.8%) were defined as the as the PAR-high group. The 3-and 5-year OS rates were 60.2% and 51.7% in the PAR-low group and 30.2% and 18.9% in the PAR-high group, respectively. There were significant differences in OS (p=0.005). The PAR was therefore selected for the final multivariate analysis model [hazard ratio=1.997, 95% confidence interval (CI)=1. 230-3.241, p=0.037]. On comparing the perioperative clinical course between the PARhigh and PAR-low groups, there were marginally significant differences in the postoperative surgical complications and intraoperative blood loss between the groups. Conclusion:The PAR had clinical influence on the long-term oncological outcomes of esophageal cancer patients and might thus be a promising prognostic factor for esophageal cancer patients.Esophageal cancer is the eighth-most common cancer and the sixth leading cause of cancer-related mortality worldwide (1, 2). Standard treatment for resectable esophageal cancer is perioperative adjuvant treatment and esophagectomy (3,4). The survival rate after curative treatment has gradually improved thanks to improvements in perioperative management and perioperative adjuvant treatment and the introduction of minimally invasive surgery.However, more than half of patients experience recurrence, even after curative treatment. Once a patient's disease recurs, the prognosis is poor (5, 6). Therefore, it is necessary to identify prognostic factors in order to introduce more aggressive treatment. Recently, perioperative nutrition and inflammation have been shown to be associated with oncological outcomes in various malignancies (7,8). Previous studies demonstrated that perioperative malnutrition and systemic inflammation accelerated tumor growth and enhanced micrometastasis (9, 10). Therefore, assessing a patient's preoperative nutritional and inflammation status is important. If physicians can manage and control the perioperative nutrition and inflammation status using optimal screening tools, they may be able to improve a patient's survival. However, screening tools for evaluating both the perioperative nutrition status and inflammation status in esophageal cancer patients are limited at present.

Background/Aim: The present study evaluated the clinical characteristics and prognostic factors of gastric cancer (GC) patients with synchronous and metachronous other primary cancer who received curative treatment for GC. Patients and Methods: The study included 244 patients who underwent curative treatment for GC between 2005 and 2018. The risk factors for the overall survival (OS) and recurrencefree survival (RFS) were identified. Results: A total of 244 patients were included in this study. Among them, 58 patients were diagnosed with synchronous and metachronous other primary cancer. When comparing the patient background characteristics and clinical course between GC patients without and with synchronous and metachronous other primary cancer, the background, postoperative surgical complications, and details of adjuvant treatment were similar between the two groups. The 3-and 5-year OS rates in GC patients with synchronous and metachronous other primary cancer were 69.7% and 48.0%, respectively, while those in patients without synchronous and metachronous other primary cancer were 80.6% and 74.3%, respectively, showing a statistically

No abstract

No abstract